Bugamed Biotechnology

What Bugamed Biotechnology does

Bugamed Biotechnology (legal entity: Bugamed Biyoteknoloji Sanayi ve Ticaret A.Ş.) is a privately held Turkish biomaterials manufacturer founded in 2017 in Eskişehir by Gamze Kara Magden. The company produces critical raw materials for the pharmaceutical, medical device, and cosmetics industries, organized under four product brands: BUGA-CoL (a comprehensive collagen portfolio including Type I and Type II atelocollagen, telocollagen, fibrillar collagen, hydrolyzed collagen, marine collagen, sponge collagen, and undenatured collagen, sourced from BSE-free bovine tendon, chicken sternum, and fish skin), BUGA-HYA (hyaluronic acid from rooster comb and sodium hyaluronate), BUGA-SF (hydrolyzed silk fibroin and silk fibroin solutions), and BUGA-Musa (plant-based protein extracts from banana peel waste). Underlying technology centers on proprietary extraction, purification, and formulation methods compliant with TSE EN ISO 22442, European and US Pharmacopeia, ISO 10993, ISO 13485, and FDA viral inactivation standards, with a circular bioeconomy model that converts organic waste into high-purity biomaterials.

The business model is B2B direct sales of biomaterial raw materials to enterprise customers in three target segments: pharmaceutical manufacturers (drug delivery, injectables, regenerative medicine), medical device companies (wound dressings, dental membranes, implants, tissue engineering scaffolds), and cosmetics firms (anti-aging, moisturizers, dermal fillers, vegan ingredients). Pricing is inquiry-based with no public price list, products are offered in research and commercial packaging sizes, and revenue is supplemented by R&D and custom biomaterial development services. The company also pursues longer-term R&D programs in bioactive dressings, dental membranes, injectable products, 3D scaffold design, and bone and cartilage tissue engineering, signaling an intent to move from raw material supply toward higher-value finished regenerative medicine solutions. Operations are anchored by co-location at Eskişehir Osmangazi University (ESOGÜ) Technopark and a dedicated manufacturing facility in the 75.Yıl district of Odunpazarı, Eskişehir, with capital supported by two disclosed funding rounds (2020 and 2023) totaling approximately $213K USD from Alesta Yatırım and TRANGELS, plus an undisclosed December 2023 investment.

Name

Bugamed Biotechnology

Legal name

Bugamed Biyoteknoloji Sanayi ve Ticaret A.Ş.

Website

https://bugamed.com.tr

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Bugamed Biotechnology is a Turkish biomaterials manufacturer founded in 2017 that produces medical-grade collagen, hyaluronic acid, silk fibroin, and plant-based proteins for pharmaceutical, medical device, and cosmetics companies through direct B2B sales.

Ownership category

akta.pro rank

Product category

Biotechnology Raw Materials

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates) (IMAEAOAL)

Keywords

• Medical-grade collagen
• Hyaluronic acid raw materials
• Silk fibroin biomaterials
• Tissue engineering scaffolds
• Biotech raw materials

Headquarters

HQ city

Eskisehir

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Biomaterial Raw Materials (B2B): Bugamed Biotechnology generates revenue by manufacturing and selling high-purity biomaterial raw materials to the pharmaceutical, medical device, and cosmetics industries. The product portfolio includes collagen types, hyaluronic acid, silk fibroin, and vegetable proteins sold in various forms (lyophilized powder, solutions, sponges) for use in R&D, clinical, and commercial applications.
2. R&D and Custom Development Services: The company provides R&D services and custom biomaterial development for partners in biotechnology and cosmetics, contributing to revenue through project-based engagements.
3. Investment Funding: Bugamed Biotechnology received new investment funding in December 2023 (per hibya news), indicating external capital injection to support company growth and operations.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Bugamed Biotechnology manufactures and sells high-purity biomaterial raw materials — including multiple collagen types (atelocollagen, telocollagen, fibrillar, hydrolyzed, marine, sponge, and undenatured), hyaluronic acid from rooster comb, silk fibroin, and plant-based proteins — for use as inputs in pharmaceutical, medical device, and cosmetic industry products. The company also conducts R&D in tissue engineering, 3D scaffold design, bioactive dressings, dental membranes, and injectable biotechnological products, leveraging a circular bioeconomy that converts organic waste into certified biomaterials.

Product overview

Bugamed Biotechnology is a biotechnology company founded in 2017 in Eskişehir, Turkey, providing innovative and sustainable raw material solutions for the pharmaceutical, medical device, and cosmetic industries. Its product portfolio centers on protein-based biomaterials, organized into three main categories: (1) Collagen-based products spanning atelocollagen (Type I and II, in solution and lyophilized forms), telocollagen, fibrillar collagen, sponge collagen, marine collagen, hydrolyzed collagen, and undenatured collagen — all sourced from bovine tendon, chicken sternum, or fish skin; (2) Hyaluronic Acid products including rooster comb-derived HA in solution and sponge forms, and chemically produced sodium hyaluronate; and (3) Silk Fibroin products including hydrolyzed silk fibroin (vegan protein) and sterile-filtrated silk fibroin solutions. Additionally, the company offers Musa Sapientum (banana peel) vegetable protein extracts in solution and lyophilized forms, reflecting its circular bioeconomy approach. Complementing the product catalog, the company maintains active R&D programs in bioactive dressings, dental membranes, tissue engineering, injectable products, 3D scaffolding design, bone and cartilage tissue studies, and biotechnology for cosmetics. The company is committed to sustainability, transforming organic waste into high-tech biomaterials.

Differentiator

Problem solved

Functional benefit

Brands

• BUGA-CoL: Collagen product line including Atelocollagen, Telocollagen, Hydrolyzed Collagen, Undenatured Collagen, Fibrillar Collagen, Marine Collagen, and Sponge Collagen products.
• BUGA-HYA
• BUGA-SF
• BUGA-Musa

Quantifiable outcome

• Bovine Collagen Solution composition at 85% concentration with 76% purity referenced on corporate page

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Eskişehir Osmangazi University TechnoparkcoreStrategic or Co-development PartnerBugamed Biotechnology is co-located within the Eskişehir Osmangazi University Technopark (Meşelik Campus), enabling close collaboration with academia and access to research infrastructure. This partnership supports the company's R&D activities in tissue engineering, biomaterials, and biotechnology applications.
• Industry Leaders (unspecified)minorStrategic or Co-development PartnerBugamed Biotechnology states it works with strong industry partners and sector leaders to develop innovative solutions and offer a broader range of services to clients. Specific partner names are not disclosed on the website.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• GELITA: GELITA is the world's largest manufacturer of collagen peptides and gelatin for pharmaceutical, medical device, and nutraceutical applications. It directly competes with Bugamed's hydrolyzed collagen and medical-grade collagen portfolio across shared pharma, medical device, and nutrition customer segments.
• Rousselot (Darling Ingredients): Rousselot produces collagen and gelatin ingredients, including medical-grade and BSE-controlled variants under the X-Pure brand, for pharma, medical device, and nutrition customers. Its endotoxin-controlled and viral-inactivated collagen products overlap directly with Bugamed's BUGA-CoL portfolio for medical device and injectable applications.
• Bioiberica: Bioiberica is a Spanish life sciences company producing hyaluronic acid, collagen, and glucosamine for pharmaceutical, medical device, and joint-health applications. It is a direct peer to Bugamed across the HA and collagen raw material lines, particularly for osteoarthritis and wound care indications.
• Contipro: Contipro is a Czech manufacturer of hyaluronic acid and related biopolymers serving medical device, pharmaceutical, wound healing, and cosmetics customers. Its HA product range and lyophilized forms closely parallel Bugamed's BUGA-HYA line for tissue engineering and dermatology.
• Symatese: Symatese is a French manufacturer of collagen, hyaluronic acid, and biopolymer-based medical devices for wound care, aesthetics, and regenerative medicine. It is a direct peer in collagen sponges and HA-based medical device substrates, mirroring Bugamed's bioactive dressing and dental membrane programs.
• Seikagaku Corporation: Seikagaku is a Japanese specialty pharmaceutical company focused on hyaluronic acid and glycosaminoglycan-based products for joint health, ophthalmology, and tissue engineering. It is a direct peer in pharma-grade HA, overlapping with Bugamed's rooster comb-derived hyaluronic acid for orthopedic and ophthalmic applications.

Emerging players

• CollPlant Biotechnologies: CollPlant is an Israeli regenerative medicine company producing recombinant human collagen from genetically engineered tobacco plants for medical devices, 3D bioprinting, and aesthetics. It is an emerging peer competing in the next-generation collagen space relevant to Bugamed's tissue engineering and wound healing programs.

Broad incumbents

• Croda International: Croda International is a large UK specialty chemicals company with a life sciences portfolio spanning pharma excipients, hyaluronic acid, and skin care actives. It is a broad incumbent that competes with Bugamed across the cosmetics and pharmaceutical segments but as part of a much wider ingredient portfolio rather than a biomaterials specialist.
• Evonik Industries: Evonik is a major German specialty chemicals company whose Health Care division supplies pharmaceutical excipients, biodegradable polymers (RESOMER), and specialty biomaterials for medical devices. It is a broad incumbent serving many of the same medical device and pharma customers Bugamed targets.
• DSM-Firmenich (dsm-firmenich): dsm-firmenich is a Dutch-Swiss specialty ingredients company formed from the merger of DSM and Firmenich, with biomedical materials, vitamins, and personal care actives. It is a broad incumbent competing with Bugamed in pharma-grade biomaterials and cosmetics ingredients through its broader portfolio of nutritional and personal care offerings.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/bugamedbio
• LinkedInlinkedin.com/company/bugamed

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bugamed Biotechnology